The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 73-80

  Chen, Xi ^a   Zhang, Mu ^a   Liu, Lian Xin ^a  

^a HARBIN UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Gankyrin; MDM2; Multidrug resistant portein; Resistance

Indexed keywords

ARSENIC TRIOXIDE; FLUOROURACIL; GANKYRIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SERINE; UNCLASSIFIED DRUG; VERAPAMIL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; STOMACH CANCER; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OXIDES; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; STOMACH NEOPLASMS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VERAPAMIL;

EID: 68249149693     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000408     Document Type: Article

References (38)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
2. Marasca R, Zucchini P, Galimberti S, et al: Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 84: 963-968, 1999.
3. Zhang T, Wang SS, Hong L, Wang XL and Qi QH: Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res 22: 61-68, 2003.
4. Chan JY, Siu KP and Fung KP: Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells. Cancer Lett 236: 250-258, 2006.
5. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 25: 77-84, 2007.
6. Ejendal KF and Hrycyna CA: Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 3: 503-511, 2002.
7. Deeley RG, Westlake C and Cole SP: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-899, 2006.
8. Keppler D, Leier I, Jedlitschky G and König J: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact 111-112: 153-161, 1998.
9. Schläwicke Engström K, Broberg K, Concha G, Nermell B, Warholm M and Vahter M: Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect 115: 599-605, 2007.
10. Kala SV, Neely MW, Kala G, et al: The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275: 33404-33408, 2000.
11. Seo T, Urasaki Y and Ueda T: Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance. Int J Hematol 85: 26-31, 2007.
12. Ovelgönne HH, Wiegant FA, Souren JE, Van Rijn H and Van Wijk R: Enhancement of the stress response by low concentrations of arsenite in arsenite-pretreated Reuber H35 hepatoma cells. Toxicol Appl Pharmacol 132: 146-155, 1995.
13. Kojima C, Qu W, Waalkes MP, Himeno S and Sakurai T: Chronic exposure to methylated arsenicals stimulates arsenic excretion pathways and induces arsenic tolerance in rat liver cells. Toxicol Sci 91: 70-81, 2006.
14. Filippova M and Duerksen-Hughes PJ: Inorganic and dimethylated arsenic species induce cellular p53. Chem Res Toxicol 16: 423-431, 2003.
15. Jiang XH, Wong BC, Yuen ST, et al: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 91: 173-179, 2001. Erratum in: Int J Cancer 93: 916, 2001.
16. Yang Y, Li CC and Weissman AM: Regulating the p53 system through ubiquitination. Oncogene 23: 2096-2106, 2004.
17. Higashitsuji H, Higashitsuji H, Itoh K, et al: The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8: 75-87, 2005.
18. Shao QS, Ye ZY, Ling ZQ and Ke JJ: Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol 11: 3451-3456, 2005.
19. Subbarayan PR, Lima M and Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 46: 557-561, 2007.
20. Wu XX, Ogawa O and Kakehi Y: Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol 24: 1489-1497, 2004.
21. Liu J, Chen H, Miller DS, et al: Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60: 302-309, 2001.
22. Sheehan D, Meade G, Foley VM and Dowd CA: Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J 360: 1-16, 2001.
23. Wang HF and Lee TC: Glutathione S-transferase pi facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells. Biochem Biophys Res Commun 192: 1093-1099, 1993.
24. Sakurai T, Ochiai M, Kojima C, et al: Role of glutathione in dimethylarsinic acid-induced apoptosis. Toxicol Appl Pharmacol 198: 354-365, 2004.
25. Leslie EM, Haimeur A and Waalkes MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1) Evidence that a tri-glutathione conjugate is required. J Biol Chem 279: 32700-32708, 2004.
26. De Rosa MF, Ackerley C, Wang B, Ito S, Clarke DM and Lingwood C: Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. J Biol Chem 283: 4501-4511, 2008.
27. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III and Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4: 855-863, 2005.
28. Oguri T, Bessho Y, Achiwa H, et al: MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 6: 122-127, 2007.
29. Miller WH Jr: Molecular targets of arsenic trioxide in malignant cells. Oncologist 7 (Suppl 1): 14-19, 2002.
30. Luo Y and Leverson JD: New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Oncologist 7 (Suppl 1): 14-19, 2002.
31. Krzywda S, Brzozowski AM, Al-Safty R, et al: Crystallization of gankyrin, an oncoprotein that interacts with CDK4 and the S6b (rpt3) ATPase of the 19S regulator of the 26S proteasome. Oncologist 7 (Suppl 1): 14-19, 2002.
32. Lozano G and Zambetti GP: Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell 8: 3-4, 2005.
33. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J and Mayer RJ: Gankyrin: a new oncoprotein and regulator of pRb and p53. Cancer Cell 8: 3-4, 2005.
34. Mahajan A, Guo Y, Yuan C, Weghorst CM, Tsai MD and Li J: Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16. J Mol Biol 373: 990-1005, 2007.
35. Sdek P, Ying H, Chang DL, et al: MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699-708, 2005.
36. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004.
37. Shangary S and Wang S: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241, 2009.
38. Shangary S, Qin D, McEachern D, et al: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105: 3933-3938, 2008.